- Home
- KZIA vs DOMH Comparison
KZIA vs DOMH Comparison
Compare KZIA & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- DOMH
- Stock Information
- Founded
- KZIA 1994
- DOMH 1967
- Country
- KZIA Australia
- DOMH United States
- Employees
- KZIA N/A
- DOMH N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- DOMH Health Care
- Exchange
- KZIA Nasdaq
- DOMH Nasdaq
- Market Cap
- KZIA 6.0M
- DOMH 74.9M
- IPO Year
- KZIA 1999
- DOMH N/A
- Fundamental
- Price
- KZIA $0.96
- DOMH $5.25
- Analyst Decision
- KZIA Strong Buy
- DOMH
- Analyst Count
- KZIA 2
- DOMH 0
- Target Price
- KZIA $11.50
- DOMH N/A
- AVG Volume (30 Days)
- KZIA 384.7K
- DOMH 1.5M
- Earning Date
- KZIA 03-26-2025
- DOMH 05-08-2025
- Dividend Yield
- KZIA N/A
- DOMH 5.93%
- EPS Growth
- KZIA N/A
- DOMH N/A
- EPS
- KZIA N/A
- DOMH N/A
- Revenue
- KZIA $1,655,324.00
- DOMH $12,589,000.00
- Revenue This Year
- KZIA N/A
- DOMH N/A
- Revenue Next Year
- KZIA N/A
- DOMH N/A
- P/E Ratio
- KZIA N/A
- DOMH N/A
- Revenue Growth
- KZIA 248000.00
- DOMH 1117.50
- 52 Week Low
- KZIA $0.76
- DOMH $0.83
- 52 Week High
- KZIA $15.80
- DOMH $13.58
- Technical
- Relative Strength Index (RSI)
- KZIA 44.72
- DOMH 44.59
- Support Level
- KZIA $0.86
- DOMH $5.18
- Resistance Level
- KZIA $0.99
- DOMH $8.55
- Average True Range (ATR)
- KZIA 0.13
- DOMH 1.30
- MACD
- KZIA 0.06
- DOMH -0.56
- Stochastic Oscillator
- KZIA 29.41
- DOMH 1.45
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.